FDA discounts Vytorin-cancer link
Posted: December 23, 2009 at 5:04 a.m.
There’s no evidence that Merck & Co.’s blockbuster cholesterol drug Vytorin causes cancer, federal regulators said Tuesday. They reviewed reams of data after a patient study last year raised suspicions of a link, weakening sales already hurt by questions about the drug’s effectiveness.
This story is only available from the archives. Click here to contact the online desk.
Business, Pages 24 on 12/23/2009
(Advertisement)
« Previous Story
State Street to buy unit from Intesa
State Street Corp. said Tuesday that it will buy the securities services business of Italian banking group Intesa Sanpaolo for about $1.87 billion in cash. Read »
Next Story »
U.S.: Revise immunity for airlines
The Justice Department says giving American Airlines, British Airways and other partners antitrust immunity to work closer together on coordinating flights could cause fare... Read »
Comments
To report abuse or misuse of this area please hit the "Suggest Removal" link in the comment to alert our online managers. Please read our comment policy.
Use the comment form below to begin a discussion about this content.
Registration is required to make comments. Click here to LOGIN.
You can register for FREE to post comments and receive alerts.